Reteplase

drugbox
IUPAC_name = Human tissue plasminogen activator fragment


CAS_number = 133652-38-7
ATC_prefix = B01
ATC_suffix = AD07
ATC_supplemental =
PubChem =
DrugBank = BTD00013
C=1736 | H=2671 | N=499 | O=522 | S=22
molecular_weight = 39589.6 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
pregnancy_category =
legal_status =
routes_of_administration =

Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13-16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

Reteplase was approved by the Food and Drug Administration in 1996.

As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.